INmune Bio, Inc.

NasdaqCM INMB

INmune Bio, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 18,867,562

INmune Bio, Inc. Shares (Diluted, Weighted) is 18,867,562 for the Trailing 12 Months (TTM) ending September 30, 2024, a 5.07% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

INmune Bio, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 17,956,903, a 1.04% change year over year.
INmune Bio, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 17,772,913, a 19.37% change year over year.
INmune Bio, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 14,888,382, a 31.69% change year over year.
INmune Bio, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 11,305,461, a 8.91% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: INMB

INmune Bio, Inc.

CEO	Dr. Raymond Joseph Tesi M.D.
IPO Date	Feb. 4, 2019
Location	United States
Headquarters	225 NE Mizner Boulevard
Employees	11
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Key trends

Past 5 years